IVIEW-1201
Phase 2Small molecule
IVIEW-1201 is one of 42 small molecule programs targeting Viral Conjunctivitis. It is currently in Phase 2.
3
Indications
3
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
55 competitors in Keratitis
#DrugCompanyPhaseTrials
1Neoral
NovartisApproved
Avelox
BayerApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Rayos
RRoxane Laboratories
Approved
Decadron
AAspen Global Incorporated
Approved
Levaquin
WWim Janssens
Approved
Acthar
MMallinckrodt
Approved
OXERVATE
DDompé Farmaceutici S.p.A
Approved
Cenegermin
DDompé Farmaceutici S.p.A
Approved
Oxervate
DDompé Farmaceutici S.p.A
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Keratitis1 trial
Bacterial Conjunctivitis1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IVIEW-1201. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IIVIEW Therapeutics Inc.